A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy

LESSONS LEARNED: Fulvestrant 500 mg maintenance therapy showed a clinical benefit rate of 76% and median progression‐free survival of 16.1 months in patients who achieved objective responses or disease control after first‐line chemotherapy. Adverse events with fulvestrant maintenance therapy were co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Xu, Fei, Zheng, Qiufan, Xia, Wen, Ouyang, Quchang, Pang, Danmei, Yuan, Zhongyu, Shi, Yanxia, Peng, Roujun, Lu, Qianyi, Wang, Shusen
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100565/
https://ncbi.nlm.nih.gov/pubmed/33245164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13614
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados